Publicaciones en colaboración con investigadores/as de Pfizer (United States) (12)

2022

  1. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

2018

  1. Widespread white matter microstructural differences in schizophrenia across 4322 individuals: Results from the ENIGMA Schizophrenia DTI Working Group

    Molecular Psychiatry, Vol. 23, Núm. 5, pp. 1261-1269

2015

  1. Inflammation in schizophrenia: A question of balance

    Neuroscience and Biobehavioral Reviews, Vol. 55, pp. 612-626

2014

  1. Oxidative/nitrosative stress in psychiatric disorders: Are we there yet?

    Schizophrenia Bulletin, Vol. 40, Núm. 5, pp. 960-962

2013

  1. A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs

    Annals of Clinical Psychiatry, Vol. 25, Núm. 1, pp. 17-26

2011

  1. Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: Findings from the CLAMORS study

    European Neuropsychopharmacology, Vol. 21, Núm. 12, pp. 867-875

2010

  1. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort

    Schizophrenia Research, Vol. 119, Núm. 1-3, pp. 101-109

  2. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: Findings from the CLAMORS study

    Journal of Clinical Psychiatry, Vol. 71, Núm. 3, pp. 280-286

2008

  1. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study

    Schizophrenia Research, Vol. 104, Núm. 1-3, pp. 1-12

  2. Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: A corollary from the CLAMORS study

    Schizophrenia Research, Vol. 99, Núm. 1-3, pp. 23-28

2007

  1. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia

    European Neuropsychopharmacology, Vol. 17, Núm. 6-7, pp. 456-463

  2. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study

    Schizophrenia Research, Vol. 90, Núm. 1-3, pp. 162-173